4th International Symposium on Hepatitis Care in Substance Users

Please click on the presentation title to view the posters:

Poster Number Presenters First Name Presenters Last Name Title of Presentation
1 Farsana  Ahmad
Engaging and Curing Active Drug Users of Hepatitis C

2 Olga Anagnostou
Recent Syringe Sharing, Long Injecting History, Past Incarceration and Not Living with the Family are Independently Associated with Hepatitis C Virus (HCV) Infection among People who Inject Drugs (PWID) in Greece

3 Amber  Arain
Pilot Study: Combining Formal and Peer Education with Fibroscan to Increase HCV Screening and Treatment in Persons Who Inject Drugs

4 Amber  Arain
Uptake for HCV Screening and Treatment in Persons in Opiate Substitution Therapy (POST) in Belgium

5 Elisabeth  Avril
From Awareness to Treatment: A Comprehensive HCV Model of Care

6 Elisabeth  Avril
The Mobile Hepatitis Screening Program: An Innovative Project among People who Use Drugs in Paris Region

7 David  Baker
Treating Hepatitis C, HIV and Opiate Dependency in a Sydney General Practice: Opportunities and Challenges

8 David  Baker
Fibroscan Screening to Detect Advance Liver Disease in People Living with Hepatitis C Attending an Australian General Practice: A Pilot Program

9 Stefan  Bourgeois
The Modelled Impact of Improved Hepatitis C Virus (HCV) Treatment Strategies on HCV Prevalence among People who Inject Drugs (PWIDS) in Belgium

10 Philip  Bruggmann
Access to Hepatitis C Care for Underserved PWID: Provision Rapid Testing and Fibrosis Assessment in Drug Consumption Rooms

11 Philip  Bruggmann
Hepatitis C Virus Prevalence among People who Inject Drugs in Switzerland

12 Tony  Butler
Willingness to be Treated for Hepatitis C among Prisoners: Results from the National Prison Entrants' Bloodborne Virus and Risk Behaviour Survey (NPBBVS)

13 Kerryn  Butler
Hepatitis C and Associated Injecting Risk Behaviours in People Who Inject Drugs

14 Erika  Castro
Standard of Care of Hepatitis C in the Addiction Medicine Clinic Centre St-Martin

15 Erika  Castro
Swiss Data on Hepatitis C Treatment in People who use Drugs: The SAMMSU Cohort

16 Craig  Connelly
Hepatitis C Treatment Access Via a Community Drug Treatment Service

17 Marie  Debrus
Positive Impact of a Community-Based Educational Intervention on Access to HCV Testing in Difficult–To-Reach People who Inject Drugs: Results from the ANRS-AERLI Study

18 John  Dillon
Preferences for Hepatitis C Testing: Application of a Discrete Choice Experiment with Methadone Users in Tayside, Scotland

19 John Dillon
Can Dried Blood Spot Testing for Hepatitis C in Community Pharmacy Increase Uptake? Interim Reporting of a Quasi-Experimental Study

20 John  Dillon
How do Methadone Users Experience Community Pharmacy? A Qualitative Study to Explore the Important Attributes When Designing a Hepatitis C Virus Testing and Treatment Pathway

21 Sergii  Filippovych
Improving Quality and Scaling Up Access to HCV Treatment for the Most-At-Risk Populations within Resource Limited Settings of Ukraine

22 Emmanuel  Fortier
The Effect of Social Functioning and Living Arrangement on Treatment Intent, Specialist Assessment and Treatment Uptake for Hepatitis C Virus Infection among People with a History of Injecting Drug Use: The ETHOS Study

23 Vincenzo  Fragomeli
Hepatitis B and C Care in the Opiate Substitution Setting - An Integrated Nursing Model of Care

24 Jason  Grebely
High Connectivity is Associated with HIV Co-Infection in the Transmission Network of People with Recent Hepatitis C Virus Infection in Australia

25 Sara  Grummett
Expanding Access to Hepatitis Care among People Who Inject Drugs (PWID): One Year of Fibroscans at the Kirketon Road Centre

26 Behzad  Hajari
Estimating the Burden of Hepatitis C Virus Infection in Iran: How the Enhanced Antiviral Treatments can Prevent the Rising Burden

27 Syune  Hakobyan
HCV Re-Infection in High-Risk People who Inject Drugs

28 Syune  Hakobyan
HCV HIV Co-Infected PWID Treated for HCV at Inner City Clinic

29 Peter  Higgs
Opportunistic Versus Standard Hepatitis B Vaccination for People who Inject Drugs (PWID) in the Supermix Cohort

30 Anne Lindebo  HolmØvrehus
Retention in Care and Testing Uptake are Major Obstacles to DAA Treatment among PWID Even in Integrated Services

31 Behnam  Honarvar
Blood-Borne Hepatitis in Opiate Users in Iran: A Poor Outlook and Urgent need to Change Nationwide Screening Policy

32 Vivian  Hope
Injecting and Drug Use Factors associated with Recent Hepatitis C Infection: New Findings from a National Sample of People Who Injecting Drugs in The United Kingdom (UK)

33 Alexandra  King
Indigenous Peoples in Canada and Hepatitis C – Stigma Deconstructed

34 Alexandra  King
Community-Derived Research Agenda for Indigenous Peoples with Lived Hepatitis C Experience

35 Lise  Lafferty
Identifying the Social Capital of Men in Prison Screening Positive for HCV

36 Michael  Levy
Incident Hepatitis C Cases Detected through a Custodial HCV Treatment Program

37 Gisela  Macphail
The Challenge to Engage the Whole Patient in the Era of Directly Acting Antiviral (DAA) Therapy for Hepatitis C Virus (HCV) Infections

38 Gisela  Macphail
"Fibroscan Days" as a Tool to Patient Engagement in the Cascade of Care for Hepatitis C (HCV)

39 Lisa  Maher
Pregnancy and Contraceptive Use among Young Women Who Inject Drugs in a Hepatitis C Virus Vaccine Preparedness Study

40 Natasha  Martin
HCV Treatment as Prevention for PWID: Is Reinfection Rate a Useful Outcome for Decision-Makers?

41 Natasha  Martin
HCV Transmission among HIV-Positive Men Who have Sex with Men in The UK: Recent Epidemiology and Modelling The Impact of Scaled-Up HCV Antiviral Treatment with New DAAS for Prevention

42 Marianne  Martinello
High Adherence to Short Duration Response-Guided Treatment among People with Recent HCV Infection: The ATAHC II and DARE-C I Studies

43 Mojca  Matičič
A National Multidisciplinary Healthcare Network for Treatment of Hepatitis C in People who Inject Drugs in Slovenia

44 Mojca  Matičič
Strategies to Manage the HCV Disease Burden in Slovenia

45 Tony  McNaughton
CHANGEing the Pharmacotherapy Experience for People who Use Illicit Drugs

46 Rozalyn  Milne
From Principles to Practice: Description of a Novel Equity-Based HCV Primary Care Treatment Model for PWID

47 Alberto  Moriggia
Response to DAA-Based Hepatitis C Treatment on PWUD in Substitution Therapy: First Real-Life Data from Southern Switzerland

48 Meghan  Morris
Historical and Geographical Trends in Incidence of Hepatitis C Virus (HCV) Infection among People who Inject Drugs: The Inc3 Study

49 Dung  Nguyen
Challenges on HCV Management in HCV/HIV Co-Infection Patients - Evidence from Cross-Sectional Study at NHTD (National Hospital of Tropical Diseases Hanoi - Vietnam)

50 Michael  Ninburg
HCV Testing and Linkage for People who Inject Drugs

51 Geert R obaeys
Telaprevir in Combination with Peginterferon and Ribavirin in Former Injection Drug Users with Chronic Hepatitis C: Findings of the Observational Integrate Study

52 Elizabeth  Peach
Comparison of Self-Reported Blood-Borne Virus Status with Recent Serology Results in a Local High Risk Population of People who Inject Drugs

53 Elizabeth  Peach
Access to Blood-Borne Virus Testing and Treatment in a Local High Risk Population of People who Inject Drugs

54 Elizabeth  Peach
Hazardous Alcohol Use and Concomitant Blood-Borne Virus Infection in a Local Urban Population of People who Inject Drugs: Implications for Approaches to Harm Reduction

55 David  Pieper
Engaging Substance Users in Advocacy Campaigning

56 Leona  Quewezance
Hepatitis C : Is There Hope

57 Homie  Razavi
Modelling the Impact Of Hepatitis C Virus (HCV) Treatment As Prevention Among People Who Inject Drugs (PWIDs) In Australia

58 Andre Jean  Remy
Treatment of the Hepatitis C in Prison in France in 2011-2012: More Patients Treated in Fewer Medical Jailhouse Units : Results of National Practice Survey

59 Andre Jean  Remy
Tools of Screening Viral Hepatitis B or C  in Real Life: New French Model of Care

60 Rachel  Sacks-Davis
Associations between Neighbourhood Disadvantage and Prescription Opiate Injection in Montreal, Canada

61 Daniela van  Santen
HIV and Hepatitis C Treatment Uptake among People Who Use Drugs from the Amsterdam Cohort Studies, 1985-2013

62 Jane  Scarborough
Care Provided for Hepatitis C: Congruence Between Patient Self-Identity and Stereotypes Applied by General Practitioners

63 Nick  Scott
Cost-Effectiveness of Treating Chronic Hepatitis C Virus with Direct-Acting Antivirals in People who Inject Drugs in Australia

64 Nikrant  Shrestha
Integrating a Hepatitis C Peer Support Worker in a Public Drug Treatment Clinic

65 Brian  Stephens
Dry Blood Spot (DBS) Testing in Injecting Drug Users

66 Jack  Stone
The Potential Impact of a Hepatitis C Vaccine for People who Inject Drugs: Is a Vaccine needed in the Age of Direct-Acting Antivirals?

67 Jan  Tait
Managed Care Networks Increase HCV Testing and Referral within Community Drug Services

68 Kjersti  Ulstein
Feasibility and Efficacy of Sofosbuvir-Based Regimens for Treatment of HCV-Infection in a Low Threshold Setting

69 Sally  Watkinson
Integrated Hepatitis C Services in Drug and Alcohol Settings Enable Engagement and Access to Care – A Cascade of Care

70 Ioannis  Xynotroulas
Treatment of Intravenous Drug Users (Idus) with Chronic Hepatitis C, Receiving Opioid Replacement with Buprenorphine in Central Greece. Effectiveness, Tolerability and Compliance